Nucleix Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
Retrieved on:
Thursday, June 3, 2021
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleixs highly sensitive EpiCheck platform.
Key Points:
- Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleixs highly sensitive EpiCheck platform.
- The collaboration will focus initially on evaluating methylation markers believed to be important for the characterization of lung cancer subtypes.
- For those markers that demonstrate efficacy in helping with this characterization, Nucleix will lead the development of new assays.
- MD Anderson will work to validate assays using in vitro and in vivo cell lines, preclinical models and clinical samples.